All In MedTech

FDA Clearance Tracker · P920023-S002

UROLUME(TM)ENDOURETHRAL WALLSTENT(R) PROSTHESIS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 27, 1996 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 27, 1996

Approved

Time to decision

18 days

Received Sep 9, 1996. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P920023-S002
Device name
UROLUME(TM)ENDOURETHRAL WALLSTENT(R) PROSTHESIS
Applicant location
Marlboro, MA
Received
Sep 9, 1996
Decided
Sep 27, 1996
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P920023

Device type

Device class
Class III

Every decision under product code MER

FDA's approval statement

As written in FDA's record.

APPROVAL TO INCREASE THE NUMBER OF INVESTIGATIONAL SITES FROM 7 TO 8 FOR THE "POST APPROVAL STUDY FOR THE UROLUME ENDOPROSTHESIS FOR TREATING RECURRENT BULBAR URETHRAL STRICTURE DISEASE

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.